Treace Announces Full Commercial Release of New Technologies for Bunion and Associated Midfoot Surgery | New

PONTE VEDRA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving fundamental change in the surgical field of treatment of hallux valgus (commonly known as bunions), today announced the full commercial release of several new technologies previewed at the American College of Foot’s February 2022 Annual Scientific Conference and Ankle Surgeons (ACFAS), including:

The Lapiplasty® 3-n-1™ Cutting Guide: An advanced instrument specifically developed as part of efforts to continuously advance the speed and reproducibility of the Lapiplasty® 3D Bunion Correction™ procedure. The 3-n-1™ Guide combines three separate instruments into one precision tool aimed at reducing surgical time and increasing the reproducibility and efficiency of the Lapiplasty® procedure. A recent survey of surgeon users demonstrated a significant 15% reduction in the time required to perform a Lapiplasty® procedure when using the 3-n-1™ Guide1.

The Lapiplasty® S4A Anatomic Veneer Kit: The S4A system represents the next generation of Lapiplasty® titanium fixation technology and offers foot and ankle surgeons an additional fixation option when performing the Lapiplasty® procedure. 3D Bunion Correction™. S4A anatomical plates feature an advanced three-dimensional contour designed to better accommodate certain anatomical variabilities based on anatomical studies of the tarso-metatarsal joint. As with all Lapiplasty® Veneer Kits, the S4A Kit is supplied in sterile packaging for user convenience and patient safety.

SpeedRelease™ and TriTome™ Release Instruments: These new sterile-packaged, single-use tissue cutting instruments are specifically designed to provide more precise and complete surgical release of key soft tissue anatomy commonly involved in Lapiplasty procedures ® and Adductoplasty™. Proper soft tissue release is important to achieve consistent corrections of the bones involved in bunion and midfoot deformities. These new devices are designed to allow surgeons to be more efficient and effective in performing specific tissue release procedures.

John T. Treace, CEO, Founder and Member of the Board of Directors of Treace, said, “As the only company in the industry focused on advancing the standard of care in the surgical correction of the bunion and related midfoot deformities, we are excited to announce the full commercial version. of our new innovations previewed at the ACFAS annual conference earlier this year. Initial clinical feedback on these products has been excellent, and we now look forward to expanding their availability for the benefit of foot and ankle surgeons and their patients, nationwide.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company focused on advancing the standard of care for the surgical management of bunion deformities and associated midfoot correction. Bunions are complex three-dimensional deformities that originate from an unstable joint in the midfoot and affect approximately 65 million Americans, of whom Treace estimates that 1.1 million are annual surgical candidates. Treace pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, by s attacking the root cause of bunion and helping patients resume their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide additional support for patients with hallux valgus. For more information, visit www.treace.com.

1. TMC archived data, April 2022 survey

contacts:

Tracee Medical Concepts

Mark L.Hair

Chief Financial Officer [email protected]

(904) 373-5940

Investors

Gilmartin Group

Lynn Lewis or Vivian Cervantes [email protected]

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.